Voyager Therapeutics 향후 성장
Future 기준 점검 1/6
Voyager Therapeutics 의 수익은 연간 5.1% 감소할 것으로 예상되는 반면, 연간 수익은 18.4% 로 증가할 것으로 예상됩니다. EPS는 연간 8.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -44.4% 로 예상됩니다.
핵심 정보
-5.1%
이익 성장률
8.59%
EPS 성장률
| Biotechs 이익 성장 | 25.4% |
| 매출 성장률 | 18.4% |
| 향후 자기자본이익률 | -44.38% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 14 May 2026 |
최근 향후 성장 업데이트
분석 기사 • Nov 14
Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) just released its latest quarterly results and things are looking bullish...분석 기사 • Aug 09
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) just released its second-quarter report and things are looking bullish. The...Recent updates
분석 기사 • May 07
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
내러티브 업데이트 • May 04
VYGR: Leadership Transition And Future P/E Stability Will Drive Upside
Analysts have maintained their $25.00 price target for Voyager Therapeutics, noting only minor adjustments to their model inputs, including a slightly different discount rate, revenue growth assumption, profit margin forecast, and future P/E multiple. What's in the News Chief Financial Officer Nathan Jorgensen, Ph.D. notified Voyager Therapeutics on April 15, 2026, that he will resign from his role and all other positions at the company, effective May 8, 2026, to pursue a new opportunity (Key Developments).내러티브 업데이트 • Apr 19
VYGR: Future P/E Stability Will Drive Upside From Cash And Milestone Optionality
Analysts kept their price target for Voyager Therapeutics steady at $25.00, reflecting small tweaks to underlying assumptions, such as a slightly higher discount rate, modest adjustments to revenue growth and profit margin expectations, and a marginal shift in the very large future P/E input. Valuation Changes $Fair Value remained unchanged at $25.00.Seeking Alpha • Apr 13
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Summary Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations. Additional upside exists with VY1706 tau-silencing gene therapy and multiple partnered programs, though key risks hinge on upcoming clinical data and regulatory milestones. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 03
VYGR: Future P/E Stability Will Support Upside From Cash And Milestone Optionality
Analysts maintained their Voyager Therapeutics price target at $25.00, citing only minor adjustments in assumptions such as discount rate, revenue growth, profit margin and future P/E that did not materially affect their overall valuation view. Valuation Changes Fair Value: Held steady at $25.00 per share, with no change in the analysts' central estimate.내러티브 업데이트 • Mar 19
VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their Voyager Therapeutics price target steady at $25.00, with updated assumptions reflecting a slightly lower discount rate, more measured revenue growth, a much slimmer profit margin, and a very large projected future P/E multiple. Together, these factors signal a more cautious outlook on profitability while holding the same headline valuation.내러티브 업데이트 • Mar 04
VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their $25.00 price target for Voyager Therapeutics unchanged, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that offset each other overall. Valuation Changes Fair Value: $25.00 unchanged, with the updated inputs offsetting each other in the model.내러티브 업데이트 • Feb 17
VYGR: Refined Assumptions Will Reinforce Upside From Cash And Milestone Optionality
Analysts kept their $25.00 price target for Voyager Therapeutics unchanged, noting only very small tweaks in the discount rate, revenue growth assumptions, profit margin, and future P/E that do not materially alter their view. Valuation Changes Fair Value: Kept steady at $25.00, with no change in the estimated intrinsic value per share.내러티브 업데이트 • Feb 03
VYGR: Neuro Data Readouts Will Reframe Upside From Cash And Milestone Optionality
Narrative Update Analysts trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing the latest cash position of US$229m, potential partner milestones of up to US$2.4b, and progress in NeuroShuttle non viral delivery programs as key inputs to their updated outlook. Analyst Commentary Bullish analysts see the latest price target move to US$25 as a reset that still implies upside from current levels, supported by what they view as a solid capital position and a growing partnered pipeline.내러티브 업데이트 • Jan 20
VYGR: Cash Strength And Milestone Upside Will Drive Neuro Data Repricing
Narrative Update on Voyager Therapeutics Analysts have trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing strong Q3 cash of US$229m, eligibility for up to US$2.4b in partner milestones, and upcoming NeuroShuttle data as key factors shaping their outlook. Analyst Commentary Bullish analysts are adjusting their views while still highlighting what they see as solid execution and a meaningful cash position at Voyager Therapeutics.내러티브 업데이트 • Jan 06
VYGR: Cash And Milestone Optionality Will Support Upcoming Neuro Data Repricing
Analysts have trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing updated assumptions around future P/E multiples, while also highlighting the company’s Q3 cash position of US$229m, potential partner milestones of up to US$2.4b, and upcoming NeuroShuttle data as key drivers for the outlook. Analyst Commentary Bullish analysts continue to see a constructive setup for Voyager Therapeutics, even with the reduced price target, pointing to cash resources, milestone potential, and the NeuroShuttle platform as the core pieces of the story.내러티브 업데이트 • Dec 15
VYGR: Cash Runway And Milestone Potential Will Drive Upside Ahead
Analysts have reduced their price target on Voyager Therapeutics by $5 to $25 per share, reflecting a modestly higher discount rate. They continue to highlight robust cash runway, significant milestone potential, and advancing NeuroShuttle data as key long term value drivers.분석 기사 • Nov 15
Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have retraced a considerable 26% in the last month, reversing a fair...분석 기사 • Nov 14
Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) just released its latest quarterly results and things are looking bullish...분석 기사 • Sep 25
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Held Back By Insufficient Growth Even After Shares Climb 27%
Despite an already strong run, Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have been powering on, with a gain of...분석 기사 • May 27
It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year
Key Insights Voyager Therapeutics' Annual General Meeting to take place on 3rd of June Salary of US$652.1k is part of...분석 기사 • Feb 25
Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Jan 30
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Summary Voyager Therapeutics, Inc.'s TRACER platform shows strong preclinical results for BBB-crossing gene therapies, securing multi-billion dollar deals with Novartis and Neurocrine, but lacks clinical trial data. VY7523, a monoclonal antibody for early Alzheimer's treatment, is expected to yield Phase I results by mid-2025, with potential undervaluation of VYGR shares. The competitive landscape includes Denali, Roche, and AbbVie, with varying BBB-crossing strategies, highlighting the speculative nature of investing in early-stage neurological therapies. I maintain a “Strong Buy” rating on VYGR shares for long-term, high-risk tolerant investors, emphasizing the speculative but promising potential of Voyager's TRACER platform and upcoming clinical trials. Read the full article on Seeking Alpha
새로운 내러티브 • Jan 26
Developing Tau-Targeting Therapies Will Open Doors But May Encounter Setbacks
Strong partnerships and collaborations are expected to enhance revenue and earnings through milestone payments and shared R&D efforts.Seeking Alpha • Nov 18
Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
Summary Voyager Therapeutics leverages its TRACER platform for targeted gene therapies, focusing on challenging CNS diseases like Alzheimer’s and ALS. Its pipeline includes a promising Phase 1 anti-tau Alzheimer’s therapy, VY7523, with data expected in 2025, but commercialization remains years away. Current valuation metrics indicate a balanced position, trading close to book value, suggesting potential but limited near-term catalysts. Key risks include reliance on collaboration revenues and the inherent difficulty of treating CNS disorders, warranting cautious optimism and a focus on future clinical trial updates. Despite promising technology and partnerships, VYGR faces long development timelines and challenging diseases, justifying a neutral "Hold" rating but worth watchlisting for 2025 R&D progress. Read the full article on Seeking Alpha분석 기사 • Oct 17
Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders are no doubt pleased to see that the share price has bounced...Seeking Alpha • Aug 26
Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Summary Shares are trading at relative lows (down 20% YTD), but have gained +130% over the past 3 years. Collaborations with big name partners like Novartis and Neurocrine have validated Voyager's TRACER AAV capsid platform. Enabling delivery across the blood brain barrier could be extended to additional modalities outside of gene therapy. The company is still at the "science project" phase of development, lacking a clear path to market, although I appreciate management's focus on indications where surrogate endpoints have gained acceptance. I remain on the sidelines and may revisit in the late 2025 to early 2026 timeframe when the pipeline has made more progress. Read the full article on Seeking Alpha분석 기사 • Aug 09
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) just released its second-quarter report and things are looking bullish. The...분석 기사 • Aug 08
Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
With a price-to-sales (or "P/S") ratio of 2.7x Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) may be sending very bullish...Seeking Alpha • Jun 05
Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Summary Voyager Therapeutics, Inc. is a biotech company focused on developing gene-based therapies for neurological conditions. The company has made progress in its pipeline, including the start of the Phase 1 clinical trial for VY-TAU01, its Alzheimer's disease candidate. Voyager's strong revenue-driver partnerships and financial stability make it a "Strong Buy" for long-term investors. Read the full article on Seeking Alpha분석 기사 • Mar 15
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have had a really impressive month, gaining 28% after a shaky period...Seeking Alpha • Mar 08
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Summary Voyager Therapeutics, a drug delivery specialist focused on AAV vectors for gene therapies, has faced many challenges, including partners walking away from deals, disappointing data, and management changes. The company has recently gained momentum through new partnerships and drug programs, attracting more than $8 billion in potential development and commercial milestone payments from three major pharma partners. Voyager's unique TRACER Capsid discovery platform and focus on gene therapy delivery make it an intriguing investment opportunity in the biotech industry. Investors will need to be patient with this company as it targets hard-to-treat CNS disease such as Alzheimer's and Parkinson's, but it's at the forefront of a promising field and I believe its best days are ahead of it. Read the full article on Seeking Alpha분석 기사 • Mar 04
What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Today is shaping up negative for Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders, with the analysts delivering...분석 기사 • Jan 04
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
The Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) share price has done very well over the last month, posting an excellent...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 76 | -116 | -126 | -100 | 8 |
| 12/31/2027 | 62 | -101 | -104 | -69 | 11 |
| 12/31/2026 | 47 | -95 | -112 | -109 | 11 |
| 3/31/2026 | 36 | -117 | -130 | -128 | N/A |
| 12/31/2025 | 40 | -120 | -135 | -132 | N/A |
| 9/30/2025 | 31 | -127 | -119 | -117 | N/A |
| 6/30/2025 | 43 | -108 | -116 | -114 | N/A |
| 3/31/2025 | 67 | -85 | -114 | -112 | N/A |
| 12/31/2024 | 80 | -65 | -19 | -15 | N/A |
| 9/30/2024 | 164 | 26 | -29 | -25 | N/A |
| 6/30/2024 | 144 | 9 | -22 | -18 | N/A |
| 3/31/2024 | 119 | -3 | 8 | 13 | N/A |
| 12/31/2023 | 250 | 132 | 75 | 78 | N/A |
| 9/30/2023 | 158 | 52 | 86 | 89 | N/A |
| 6/30/2023 | 195 | 96 | 91 | 94 | N/A |
| 3/31/2023 | 191 | 99 | 74 | 77 | N/A |
| 12/31/2022 | 41 | -46 | -15 | -13 | N/A |
| 9/30/2022 | 71 | -17 | 9 | 11 | N/A |
| 6/30/2022 | 31 | -60 | 4 | 6 | N/A |
| 3/31/2022 | 32 | -71 | 1 | 2 | N/A |
| 12/31/2021 | 37 | -71 | -55 | -54 | N/A |
| 9/30/2021 | 16 | -93 | -92 | -87 | N/A |
| 6/30/2021 | 132 | 18 | -100 | -91 | N/A |
| 3/31/2021 | 160 | 39 | -100 | -89 | N/A |
| 12/31/2020 | 171 | 37 | -109 | -97 | N/A |
| 9/30/2020 | 197 | 40 | -110 | -98 | N/A |
| 6/30/2020 | 100 | -61 | -103 | -95 | N/A |
| 3/31/2020 | 117 | -41 | -113 | -105 | N/A |
| 12/31/2019 | 104 | -44 | N/A | 49 | N/A |
| 9/30/2019 | 74 | -54 | N/A | 48 | N/A |
| 6/30/2019 | 55 | -59 | N/A | 52 | N/A |
| 3/31/2019 | 12 | -96 | N/A | 61 | N/A |
| 12/31/2018 | 8 | -88 | N/A | -16 | N/A |
| 9/30/2018 | 12 | -78 | N/A | -6 | N/A |
| 6/30/2018 | 11 | -81 | N/A | -5 | N/A |
| 3/31/2018 | 10 | -74 | N/A | 2 | N/A |
| 12/31/2017 | 10 | -71 | N/A | -61 | N/A |
| 9/30/2017 | 6 | -74 | N/A | -60 | N/A |
| 6/30/2017 | 8 | -59 | N/A | -54 | N/A |
| 3/31/2017 | 11 | -50 | N/A | -47 | N/A |
| 12/31/2016 | 14 | -40 | N/A | -42 | N/A |
| 9/30/2016 | 17 | -34 | N/A | -39 | N/A |
| 6/30/2016 | 18 | -32 | N/A | -36 | N/A |
| 3/31/2016 | 20 | -30 | N/A | -33 | N/A |
| 12/31/2015 | 17 | -38 | N/A | 41 | N/A |
| 9/30/2015 | 12 | -35 | N/A | 46 | N/A |
| 6/30/2015 | 7 | -32 | N/A | 50 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: VYGR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: VYGR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: VYGR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: VYGR 의 수익(연간 18.4%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: VYGR 의 수익(연간 18.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: VYGR는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 15:09 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Voyager Therapeutics, Inc.는 25명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Brian Skorney | Baird |
| Jack Allen | Baird |
| Aydin Huseynov | Benchmark Company |